Lipid CME
LECTURECME

Rapid-Fire Roundtable: Addressing Clinical Challenges Regarding the Use of PCSK9 Inhibitors

Author(s)/Faculty: Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FASPC, FCCP, FACC; Michael Miller, MD, FACC, FAHA; James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Release Date: 1/14/2019Expiration Date: 1/13/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to be safe and efficacious in both current and ongoing clinical trials. Their use in patients has been demonstrated to lower low-density lipoprotein cholesterol levels significantly and reduce major adverse cardiovascular events. However, many clinicians still do not use these medications in their daily practice. Physicians need to be aware of the latest clinical evidence regarding PCSK9 inhibitors and overcome the barriers associated with obtaining these drugs for their patients. In this educational activity, expert physicians will discuss the efficacy and safety of PCSK9 inhibitors, as well as provide guidance regarding when to prescribe these medications and how to obtain them for their patients.